ClinicalTrials.gg

Erectile Dysfunction clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 702 studies for Erectile Dysfunction across more than 10 countries. 125 are recruiting or about to start. 563 of them are mainly about Erectile Dysfunction (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

ClinicalTrials.gov finds 751 studies for Erectile Dysfunction. How that becomes 701 here

This page counts the studies the registry files under Erectile Dysfunction, and those it files under no condition that list Erectile Dysfunctionthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 751Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −20List Erectile Dysfunction as a condition, but the registry did not file them under itMost often written as “Erectile Dysfunction Following Radical Prostatectomy” (13), “Erectile Dysfunction Associated With Type 2 Diabetes Mellitus” (2), and “Erectile Dysfunction With Diabetes Mellitus” (2). The registry filed them under other conditions only, most often Prostatic Neoplasms (13) and Urinary Incontinence (3).
  3. −30Match it another way25 name it in the title, 1 in a keyword, and 4 by a synonym or other text the search reads.
  4. 701The count on this page30 of them list Erectile Dysfunction in their own words; the registry filed them under no condition.

Status

Completed
397
Status unknown
111
Recruiting
78
Not yet recruiting
40
Terminated
29
Withdrawn
24

Phase

Phase 3
114
Phase 4
105
Phase 2
90
Phase 1
79
Early Phase 1
3

Where

United States
180
Egypt
56
China
39
Italy
36
Turkey
32
France
30

Who develops what

Add Erectile Dysfunction to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 12 programs from 8 companies, 11 with this as their studies’ main aim; 3 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Hanmi Pharmaceutical and Sanofi here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
sildenafilRecent, repeated
Evidence
  • NCT07231185 · Aspargo Labs, Inc · Phase 2 · live · comparator · “Pfizer Viagra” · registered Nov 2025
  • NCT06064448 · Xintian Pharmaceutical · Phase 4 · comparator · “Sildenafil” · registered Sep 2023
  • NCT02798159 · Vietstar Biomedical Research · Phase 3 · comparator · “Sildenafil Citrate 50mg” · registered Jun 2016
  • NCT01321489 · laborato rio teuto brasileiro s a · Phase 3 · comparator · “Sildenafil Citrate 20mg Tablet Sublingual” · registered Mar 2011
  • NCT01122264 · Eli Lilly and Company · Phase 4 · comparator · “Sildenafil Citrate” · registered May 2010
Viatris Inc.64% of its industry studiesUS: off-patent, 35 generics marketedEU: off-patent, 6 generics authorized22 studies

3 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
W2505☆ Track1 live phase-3 study: NCT07859202GL Pharm Tech Corporation
hip2602☆ Track1 live phase-3 study: NCT07899073Hanmi Pharmaceutical Company Limited
hpp2602-2☆ Track1 live phase-3 study: NCT07899073Hanmi Pharmaceutical Company Limited

The 3 in phase 3 with the nearest primary completion, of 12 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jul 2027 est.W2505 · GL Pharm Tech Corporation · Phase 3 main aimNCT07859202 The Purpose of This Study is to Evaluate the Efficacy and Safety of W2505. — primary endpoint: Change from Baseline in International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score · 228 enrolled
  • Sep 2027 est.hip2602, hpp2602-2 · Hanmi Pharmaceutical Company Limited · Phase 3 main aimNCT07899073 A Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients — primary endpoint: Change of IIEF-EF domain score from baseline after 12 weeks · 225 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Erectile Dysfunction studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here PDE5 inhibitors 8 open · Androgens 9 · Statins 3

Coming up

44studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger. 2 (3%) take children under 18. 3 (4%) are for women only and 71 (91%) for men only; 7 (9%) take healthy volunteers.

Recruiting studies that take each age, of 78
AgeWomenMen
101 (1%)2 (3%)
186 (8%)35 (45%)
306 (8%)57 (73%)
407 (9%)74 (95%)
507 (9%)70 (90%)
657 (9%)68 (87%)
757 (9%)53 (68%)
856 (8%)33 (42%)

Across all 702 studies, recruiting or not: 49% stop at 75 or younger and 29% at 65; 4% take children; 1% are for women only and 95% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Erectile Dysfunction studies take

Of 24 phase 2 interventional studies under Erectile Dysfunction, half reached primary completion within 28 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 15 mo1–19 · 18 studies——
Phase 228 mo16–32 · 24 studies——
Phase 325 mo10–30 · 16 studies——
Phase 411 mo8–27 · 16 studies——
Interventional, no phase32 mo14–52 · 137 studies—30 mo15–52 · 115 studies
Observational36 mo11–77 · 41 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 702. Browse all 702 → or search them.